MA40517A - Procédé pour préparation du facteur stimulant les colonies de granulocytes (g-csf) - Google Patents

Procédé pour préparation du facteur stimulant les colonies de granulocytes (g-csf)

Info

Publication number
MA40517A
MA40517A MA040517A MA40517A MA40517A MA 40517 A MA40517 A MA 40517A MA 040517 A MA040517 A MA 040517A MA 40517 A MA40517 A MA 40517A MA 40517 A MA40517 A MA 40517A
Authority
MA
Morocco
Prior art keywords
csf
stimulating factor
colony stimulating
granulocyte colony
preparation
Prior art date
Application number
MA040517A
Other languages
English (en)
Inventor
Nehir Güler
Idil Gültepe
Irem Yenice
Mehmet Üzgün
Original Assignee
Arven Ilac Sanayi Ve Ticaret As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arven Ilac Sanayi Ve Ticaret As filed Critical Arven Ilac Sanayi Ve Ticaret As
Publication of MA40517A publication Critical patent/MA40517A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/362—Cation-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/42—Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
    • B01D15/424—Elution mode
    • B01D15/426—Specific type of solvent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/02—Separating microorganisms from their culture media

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne un nouveau procédé d'isolement et de purification de facteur de stimulation de colonies de granulocytes (g-csf) à partir d'un micro-organisme producteur de g-csf, plus spécifiquement g-csf est méthionyl g-csf humain recombinant (rmethug-csf)
MA040517A 2015-03-16 2016-03-15 Procédé pour préparation du facteur stimulant les colonies de granulocytes (g-csf) MA40517A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR201503097 2015-03-16
TR201504463 2015-04-13

Publications (1)

Publication Number Publication Date
MA40517A true MA40517A (fr) 2016-09-21

Family

ID=55453105

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040517A MA40517A (fr) 2015-03-16 2016-03-15 Procédé pour préparation du facteur stimulant les colonies de granulocytes (g-csf)

Country Status (4)

Country Link
US (1) US20180086808A1 (fr)
EP (1) EP3070099A1 (fr)
MA (1) MA40517A (fr)
WO (1) WO2016146629A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202107201YA (en) * 2018-12-28 2021-07-29 Coherus Biosciences Inc Process for producing, isolating, and purifying modified recombinant proteins
US20220195002A1 (en) * 2019-04-24 2022-06-23 Tanvex Biopharma Usa, Inc. Process for preparing granulocyte-colony stimulating factor

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPS63500636A (ja) 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
EP0220520B1 (fr) 1985-09-30 1991-09-18 Chugai Seiyaku Kabushiki Kaisha Facteur de stimulation de colonie de granulocytes humains
JPH01500483A (ja) 1986-08-11 1989-02-23 シタス　コーポレイション Ｇ‐ｃｓｆ及びそのミューテインの発現
US5055555A (en) 1989-01-05 1991-10-08 Helmut Sassenfeld Purification of G-CSF
US20080171857A1 (en) * 2005-03-17 2008-07-17 Uma Devi Komath Process for the Purification of Recombinant Granulocyte-Colony Stimulating Factor
DE102005033250A1 (de) * 2005-07-15 2007-01-18 Bioceuticals Arzneimittel Ag Verfahren zur Reinigung von G-CSF
WO2008096370A2 (fr) 2007-02-05 2008-08-14 Natco Pharma Limited Méthode nouvelle et efficace de purification de hg-csf de recombinaison
PL2341061T3 (pl) 2009-12-31 2014-09-30 Arven Ilac Sanayi Ve Ticaret As Nowy sposób wytwarzania G-CSF (czynnika stymulującego tworzenie kolonii granulocytów)
KR101831300B1 (ko) * 2010-10-29 2018-02-23 한미사이언스 주식회사 재조합 대장균으로부터 인간 과립구 콜로니 자극인자를 정제하는 방법

Also Published As

Publication number Publication date
US20180086808A1 (en) 2018-03-29
EP3070099A1 (fr) 2016-09-21
WO2016146629A1 (fr) 2016-09-22

Similar Documents

Publication Publication Date Title
MX2020013114A (es) Proceso para sintetizar 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5- il)-piridin-3-il)metoxi)benzaldehído.
WO2018198077A3 (fr) Composés hétéroaryle bicycliques fusionnés en 6-6 et leur utilisation comme inhibiteurs de lats
EA201001691A1 (ru) Антитела к гранулоцитарно-макрофагальному колониестимулирующему фактору
EA201171481A1 (ru) Способ получения высококонцентрированного препарата иммуноглобулина для подкожного применения
JOP20120351B1 (ar) عملية لتحضير 5- فلورو-1h- بيرازولوبيريدينات مستبدلة
MX2015015188A (es) Metodo de clonacion, expresion y purificacion novedoso para la preparacion de ranibizumab.
CL2019002078A1 (es) Sal de acido clorhídrico del inhibidor de pim quinasa n-{(7r)-4-[(3r, 4r, 5s)-3-amino-4-hidroxi-5-metilpiperidin-1-il]-7- hidroxi-6,7-dihidro-5h-ciclopenta[b] piridin-3-il}-6-(2,6-difluorofenil)-5-fluoropiridin-2-carboxamida; útil en el tratamiento del cáncer (divisional de solicitud 611-2018).
MX2022012671A (es) Vacuna terapeutica individualizada contra el cancer.
EA201890442A1 (ru) Получение фоторецепторов для лечения заболеваний сетчатки
MA40517A (fr) Procédé pour préparation du facteur stimulant les colonies de granulocytes (g-csf)
HUE068633T2 (hu) Eljárás negatív elektróda elõállítására
AU2022233762A1 (en) Method of treating diseases using gremlin1 antagonists
ZA202401405B (en) Compositions and methods for anti-pacap antibodies
CY1114556T1 (el) Μια νεα διαδικασια για την παρασκευη του g-csf (διεγερτικος παραγοντας αποικιων κοκκιοκυτταρων)
EA201990364A1 (ru) КРИСТАЛЛИЧЕСКИЕ И СОЛЕВЫЕ ФОРМЫ 7-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ И СПОСОБ ИХ ПОЛУЧЕНИЯ
PH12021552680A1 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of kidney diseases
ZA202501671B (en) Methods of treating graves' disease using anti-fcrn antibodies
MX2020006641A (es) Proceso para la preparacion de compuestos de pirimidinil-4-aminopi razol.
MX2022004066A (es) Oxidacion de santaleno a santalol.
EA202192840A1 (ru) Способ получения соединений карбамоилоксиметилтриазолциклогексиловой кислоты
MX2021001530A (es) Metodo de produccion de esteres carbonicos.
CN1195868C (zh) 一种体外免疫人b淋巴细胞生产人单克隆抗体的方法
EA202191578A1 (ru) Фармацевтический способ и промежуточные соединения
MX2025006477A (es) Metodos de administracion de belumosudil para el tratamiento del mieloma multiple
GB202202165D0 (en) Novel methods of therapy